Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an update.
Chimeric Therapeutics announced a $6.6 million capital raising, with CEO Dr. Rebecca McQualter set to provide further updates in an investor webinar. This capital infusion is expected to bolster the company’s operations and enhance its industry positioning, potentially benefiting stakeholders by advancing its clinical-stage programs and expanding its innovative cell therapy offerings.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian clinical-stage company specializing in cell therapy, focusing on innovative treatments for cancer patients. The company is engaged in the discovery, development, and commercialization of pioneering cell therapies, with a diverse portfolio that includes autologous CAR-T and allogeneic NK cell therapies. Chimeric is actively developing assets across multiple oncology areas with four clinical-stage programs.
Technical Sentiment Signal: Sell
Current Market Cap: A$14.81M
See more data about CHM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue